Lita A Freeman

List of Publications by Year
in descending order

21 papers	899 citations	623734 14 h-index	752698 20 g-index
21 all docs	21 docs citations	21 times ranked	1272 citing authors

#	Article	IF	Citations
1	Transgelin: a new gene involved in LDL endocytosis identified by a genome-wide CRISPR-Cas9 screen. Journal of Lipid Research, 2022, 63, 100160.	4.2	10
2	A novel loop-mediated isothermal amplification-based genotyping method and its application for identifying proprotein convertase subtilisin/kexin type 9 variants in familial hypercholesterolemia. Biochimica Et Biophysica Acta - General Subjects, 2021, , 130063.	2.4	0
3	Interleukin 10 promotes macrophage uptake of HDL and LDL by stimulating fluid-phase endocytosis. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158537.	2.4	14
4	LCAT protects against Lipoproteinâ€X formation in a murine model of drugâ€induced intrahepatic cholestasis. Pharmacology Research and Perspectives, 2020, 8, e00554.	2.4	7
5	Novel lecithin:cholesterol acyltransferase-based therapeutic approaches. Current Opinion in Lipidology, 2020, 31, 71-79.	2.7	21
6	COVIDâ€19â€"Associated dyslipidemia: Implications for mechanism of impaired resolution and novel therapeutic approaches. FASEB Journal, 2020, 34, 9843-9853.	0.5	129
7	A dual apolipoprotein C-II mimeticâ€"apolipoprotein C-III antagonist peptide lowers plasma triglycerides. Science Translational Medicine, 2020, 12, .	12.4	56
8	Incorporation of Î±-methylated amino acids into Apolipoprotein A-I mimetic peptides improves their helicity and cholesterol efflux potential. Biochemical and Biophysical Research Communications, 2020, 526, 349-354.	2.1	5
9	DENND5B Regulates Intestinal Triglyceride Absorption and Body Mass. Scientific Reports, 2019, 9, 3597.	3.3	10
10	Plasma lipoprotein-X quantification on filipin-stained gels: monitoring recombinant LCAT treatment ex vivo. Journal of Lipid Research, 2019, 60, 1050-1057.	4.2	14
11	LCAT Enzyme Replacement Therapy Reduces LpX and Improves Kidney Function in a Mouse Model of Familial LCAT Deficiency. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 423-434.	2.5	23
12	Structural properties of apolipoprotein A-I mimetic peptides that promote ABCA1-dependent cholesterol efflux. Scientific Reports, 2018, 8, 2956.	3.3	27
13	The Changing Face of HDL and the Best Way to Measure It. Clinical Chemistry, 2017, 63, 196-210.	3.2	86
14	Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism. Atherosclerosis, 2017, 267, 49-60.	0.8	148
15	A Novel APOC2 Missense Mutation Causing Apolipoprotein C-II Deficiency With Severe Triglyceridemia and Pancreatitis. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1454-1457.	3.6	35
16	Familial lecithin:cholesterol acyltransferase deficiency: First-in-human treatment with enzyme replacement. Journal of Clinical Lipidology, 2016, 10, 356-367.	1.5	82
17	Creation of Apolipoprotein C-II (ApoC-II) Mutant Mice and Correction of Their Hypertriglyceridemia with an ApoC-II Mimetic Peptide. Journal of Pharmacology and Experimental Therapeutics, 2016, 356, 341-353.	2.5	46
18	Safety and Tolerability of ACP-501, a Recombinant Human Lecithin:Cholesterol Acyltransferase, in a Phase 1 Single-Dose Escalation Study. Circulation Research, 2016, 118, 73-82.	4.5	72

#	Article	IF	Citations
19	Lipoprotein X Causes Renal Disease in LCAT Deficiency. PLoS ONE, 2016, 11, e0150083.	2.5	61
20	A Novel Apolipoprotein C-II Mimetic Peptide That Activates Lipoprotein Lipase and Decreases Serum Triglycerides in Apolipoprotein Eâ€"Knockout Mice. Journal of Pharmacology and Experimental Therapeutics, 2015, 352, 227-235.	2.5	48
21	A GCH1 Haplotype Associated with Susceptibility to Vasoocclusive Pain and Impaired Vascular Function in Sickle Cell Anemia.. Blood, 2009, 114, 575-575.	1.4	5